These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21911174)

  • 1. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: a case report.
    Sicilia-Castro D; Gomez-Cia T; Infante-Cossio P; Gacto-Sanchez P; Barrera-Pulido F; Lagares-Borrego A; Narros-Gimenez R; Garcia-Perla A; Hernandez-Guisado JM; Gonzalez-Padilla JD
    Transplant Proc; 2011 Sep; 43(7):2831-7. PubMed ID: 21911174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Face Transplant in an Advanced Neurofibromatosis Type 1 Patient.
    Krakowczyk Ł; Maciejewski A; Szymczyk C; Oleś K; Półtorak S
    Ann Transplant; 2017 Jan; 22():53-57. PubMed ID: 28138125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Multifunctional Outcome and Risks of Face Vascularized Composite Allotransplantation.
    Roche NA; Blondeel PN; Vermeersch HF; Peeters PC; Lemmens GM; De Cubber J; De Letter M; Van Lierde K
    J Craniofac Surg; 2015 Oct; 26(7):2038-46. PubMed ID: 26468783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study.
    Lantieri L; Meningaud JP; Grimbert P; Bellivier F; Lefaucheur JP; Ortonne N; Benjoar MD; Lang P; Wolkenstein P
    Lancet; 2008 Aug; 372(9639):639-45. PubMed ID: 18722868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human facial allotransplantation: a 2-year follow-up study.
    Guo S; Han Y; Zhang X; Lu B; Yi C; Zhang H; Ma X; Wang D; Yang L; Fan X; Liu Y; Lu K; Li H
    Lancet; 2008 Aug; 372(9639):631-8. PubMed ID: 18722867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second human facial allotransplantation to restore a severe defect following radical resection of bilateral massive plexiform neurofibromas.
    Gomez-Cia T; Sicilia-Castro D; Infante-Cossio P; Barrera-Pulido F; Gacto-Sanchez P; Lagares-Borrego A; Narros-Gimenez R; Garcia-Perla A; Hernandez-Guisado JM; González-Padilla JD
    Plast Reconstr Surg; 2011 Feb; 127(2):995-996. PubMed ID: 21285817
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy.
    Ahsan N; Holman MJ; Katz DA; Abendroth CS; Yang HC
    Clin Transplant; 1997 Apr; 11(2):94-7. PubMed ID: 9113443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.
    Jain A; Sharma R; Ryan C; Tsoulfas G; Orloff M; Abt P; Kashyap R; Batzold P; Sauberman L; Safadjou S; Graham M; Bozorgzadeh A
    Liver Transpl; 2008 Feb; 14(2):202-9. PubMed ID: 18236395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of maintenance immunosuppression medication on the change in kidney allograft function.
    Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ
    Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Findings of Chronic Rejection in a Face Grafted Patient.
    Petruzzo P; Kanitakis J; Testelin S; Pialat JB; Buron F; Badet L; Thaunat O; Devauchelle B; Morelon E
    Transplantation; 2015 Dec; 99(12):2644-50. PubMed ID: 25989498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First U.S. near-total human face transplantation: a paradigm shift for massive complex injuries.
    Siemionow MZ; Papay F; Djohan R; Bernard S; Gordon CR; Alam D; Hendrickson M; Lohman R; Eghtesad B; Fung J
    Plast Reconstr Surg; 2010 Jan; 125(1):111-122. PubMed ID: 19770815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The International Registry on Hand and Composite Tissue allotransplantation.
    Petruzzo P; Dubernard JM
    Clin Transpl; 2011; ():247-53. PubMed ID: 22755418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex facial reconstruction by vascularized composite allotransplantation: the first Belgian case.
    Roche NA; Vermeersch HF; Stillaert FB; Peters KT; De Cubber J; Van Lierde K; Rogiers X; Colenbie L; Peeters PC; Lemmens GM; Blondeel PN
    J Plast Reconstr Aesthet Surg; 2015 Mar; 68(3):362-71. PubMed ID: 25488328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
    Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation.
    Miyazaki T; Tagawa T; Yamasaki N; Tsuchiya T; Matsumoto K; Nagayasu T
    Transplant Proc; 2013; 45(1):356-9. PubMed ID: 23375323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
    Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
    Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.